These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9773681)

  • 1. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy.
    Border WA; Noble NA
    Kidney Int; 1998 Oct; 54(4):1390-1. PubMed ID: 9773681
    [No Abstract]   [Full Text] [Related]  

  • 2. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
    Kelly DJ; Cox AJ; Tolcos M; Cooper ME; Wilkinson-Berka JL; Gilbert RE
    Kidney Int; 2002 Jan; 61(1):31-9. PubMed ID: 11786082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta as a target for treatment in diabetic nephropathy.
    Basile DP
    Am J Kidney Dis; 2001 Oct; 38(4):887-92. PubMed ID: 11576897
    [No Abstract]   [Full Text] [Related]  

  • 4. Transforming growth factor-β/Smad signalling in diabetic nephropathy.
    Lan HY
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):731-8. PubMed ID: 22211842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.
    McGowan TA; Zhu Y; Sharma K
    Curr Diab Rep; 2004 Dec; 4(6):447-54. PubMed ID: 15539010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.
    Daniel C; Schaub K; Amann K; Lawler J; Hugo C
    Diabetes; 2007 Dec; 56(12):2982-9. PubMed ID: 17878288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
    Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting TGF could counter diabetic nephropathy.
    Greener M
    Mol Med Today; 2000 Oct; 6(10):376. PubMed ID: 11006518
    [No Abstract]   [Full Text] [Related]  

  • 9. Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy.
    Tu Y; Wu T; Dai A; Pham Y; Chew P; de Haan JB; Wang Y; Toh BH; Zhu H; Cao Z; Cooper ME; Chai Z
    Kidney Int; 2011 Jan; 79(2):199-209. PubMed ID: 20962744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
    Mizuno S; Nakamura T
    Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-beta in kidney fibrosis: a target for gene therapy.
    Border WA; Noble NA
    Kidney Int; 1997 May; 51(5):1388-96. PubMed ID: 9150449
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of TGF-beta in the progression of renal fibrosis.
    Tamaki K; Okuda S
    Contrib Nephrol; 2003; 139():44-65. PubMed ID: 12854318
    [No Abstract]   [Full Text] [Related]  

  • 13. Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy.
    Leon CA; Raij L
    J Hypertens; 2005 Nov; 23(11):1931-7. PubMed ID: 16208129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement.
    Kelly B; Petitt M; Sanchez R
    J Am Acad Dermatol; 2008 Jun; 58(6):1025-30. PubMed ID: 18485985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapies on the Horizon for Diabetic Kidney Disease.
    Khan SS; Quaggin SE
    Curr Diab Rep; 2015 Dec; 15(12):111. PubMed ID: 26458382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor beta in diabetic nephropathy.
    Border WA; Yamamoto T; Noble NA
    Diabetes Metab Rev; 1996 Dec; 12(4):309-39. PubMed ID: 9013074
    [No Abstract]   [Full Text] [Related]  

  • 17. [Diabetic nephropathy].
    Metsärinne K
    Duodecim; 2003; 119(24):2445-50. PubMed ID: 14870506
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy.
    Wang SN; LaPage J; Hirschberg R
    Kidney Int; 2000 Mar; 57(3):1002-14. PubMed ID: 10720953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy.
    Ziyadeh FN
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S38-41. PubMed ID: 18842317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes.
    Perico N; Remuzzi G
    Kidney Int; 2007 Dec; 72(12):1419-21. PubMed ID: 18046419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.